Sage Journals: Discover world-class research

Abstract

Background:

Antibodies have been proved to be effective in cancer treatment. Peroxiredoxin I (Prx I) is a potential target for cancer radiotherapy. The aim of this article is to investigate the effect of a novel phage display single-chain variable fragment (scFv) antibody targeting Prx I on human lung carcinoma cell line A549 radiosensitivity and the underlying mechanisms.

Materials and

Methods: A549 cell radiosensitivity was measured by colony-forming assay; cell cycle, cell apoptosis, and intracellular reactive oxygen species (ROS) level were determined by flow cytometer; RAD51 and γ-H2AX expression was evaluated by Western blot; and caspase 3 expression was determined by immunocytochemistry. A nude mouse bearing A549 tumor was established, and radiation sensitivity was measured to verify the in vitro data.

Results:

Prx I scFv incubation significantly increased A549 cell radiosensitivity, and this might be through enhanced intracellular ROS level and caspase 3 expression. In addition, protein expression of radiosensitivity-related proteins, RAD51 and γ-H2AX, was also modulated. The nude mouse xenograft model bearing A549 tumor treated with Prx I scFv also exibited enhanced radiosensitivity compared with the PBS group.

Conclusions:

These results suggested that Prx I scFv could become a new therapy candidate for lung cancer radiotherapy.

Get full access to this article

View all access options for this article.

References

Jemal

, Siegel

, Ward

et al. Cancer statistics. CA cancer J Clin, 2009; 59:225.

Lawenda

, Kelly

, Ladas

et al.

Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?

J Natl Cancer Inst, 2008; 100:773.

Okunieff

, Swarts

, Keng

et al. Antioxidants reduce consequences of radiation exposure. Adv Exp Med Biol, 2008; 614:165.

Kim

, Chae

, Kim

et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol, 2003; 19:285.

Chang

, Jeon

, Lee

et al. Augmented expression of Peroxiredoxin I in lung cancer. Biochem Biophy Res Commun, 2001; 289:507.

Chang

, Lee

, Jeong

et al. Peroxiredoxin I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett, 2005; 579:2873.

Zhang

, Wang

, Liu

et al. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem Pharmacol, 2008; 75:660.

Reichert

, Valge-Archer

. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov, 2007; 6:349.

Piche

, Grim

, Rancourt

et al. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res, 1998; 58:2134.

10.

Luo

, Pang

, Li

et al. Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther, 2009; 8:1.

11.

Huang

, Rio

, Nicolas

et al. A genomewide screen in Saccharomyces cerevisiae for genes that suppress the accumulation of mutations. Proc Natl Acad Sci U S A, 2003; 100:11529.

12.

Huang

, Kolodner

. A biological network in Saccharomyces cerevisiae prevents the deleterious effects of endogenous oxidative. DNA damage Mol Cell, 2005; 17:709.

13.

Park

, Cha

, Jeong

et al. Distinct physiological functions of thiol peroxidase isoenzymes in Saccharomyces cerevisiae. J Biol Chem, 2000; 275:5723.

14.

Pedrajas

, Miranda-Vizuete

, Javanmardy

et al. Mitochondria of Saccharomyces cerevisiae contain one-conserved cysteine type peroxiredoxin with thioredoxin peroxidase activity. J Biol Chem, 2000; 275:16296.

15.

Chen

, McBride

, Iwamoto

et al. Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J Neurosci Res, 2002; 70:794.

16.

Zhang

, Su

, Ai

et al. Involvement of peroxiredoxin I in protecting cells from IR-induced death. J Radiat Res, 2005; 46:305.

17.

Zhang

, Wang

, Su

. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett, 2009; 286:154.

18.

Neumann

, Cao

, Manevich

. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle, 2009; 24:4072.

19.

Rhee

, Chae

, Kim

. Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med, 2005; 38:1543.

20.

Iraqui

, Kienda

, Soeur

et al. Peroxiredoxin Tsa1 is the key peroxidase suppressing genome instability and protecting against cell death in Saccharomyces cerevisiae. PLoS Genetics, 2009; 6:e1000524.

21.

Shinohara

, Ogawa

. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell, 1992; 69:457.

22.

Ohnishi

, Taki

, Hiraga

et al. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophy Res Commun, 1998; 245:319.

23.

Taki

, Ohnishi

, Yamamoto

et al. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophy Res Commun, 1996; 223:434.

24.

Kuo

, Yang

. Gamma-H2AX—A novel biomarker for DNA double- strand breaks. In Vivo, 2008; 22:305.

25.

Chen

, Keng

, Shau

et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin 1 expression. Int J IR Oncology Biol Phys, 2006; 64:581.

26.

Crombet

, Osorio

, Cruz

et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol, 2004; 22:1646.

27.

Buchsbaum

, Zhou

, Grizzle

et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or IR therapy in a human breast cancer model. Clin Cancer Res, 2003; 9:3731.

28.

Xiao

, Horst

, Hinkle

et al. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm, 2005; 20:16.

29.

Weiner

. Fully human therapeutic monoclonal antibodies. J Immunother, 2006; 29:1.

30.

Daugherty

, DeMartino

, Law

et al. Polymerase chain reaction facilitate the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res, 1991; 19:2471.

31.

Padlan

. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol, 1991; 28:489.

32.

Hoogenboom

. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol, 1997; 15:62.

33.

Vaughan

, Williams

, Pritchard

et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol, 1996; 14:309.

34.

Park

, Smolen

. Monoclonal antibody therapy. Adv Protein Chem, 2001; 56:369.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

Downregulation of Peroxiredoxin I by a Novel Fully Human Phage Display Recombinant Antibody Induces Apoptosis and Enhances Radiation Sensitization in A549 Lung Carcinoma Cells

Abstract

Background:

Materials and

Results:

Conclusions:

Get full access to this article

References

Supplementary Material